In a recent study, researchers from Pune, along with their collaborators in Chennai and the USA, have assessed the functioning of lungs after successful tuberculosis (TB) treatment. The study, published in the journal PLoS ONE, has shown the occurrence of lung defects and chronic obstructive pulmonary disease after tuberculosis treatment.
Researchers find familial dissimilarities in proteins from two species of Mycobacterium.
An international study, led by researchers from the USA, which also included researchers from India, have designed a point-of-care testing approach for individuals suffering from TB. The study, published in the journal Science Translational Medicine and supported in part by the Bill and Melinda Gates Foundation, proposes a rapid, cost-effective, and readily accessible triage test kit that can be used at the site of patient care.
In 2018, around 1.5 million people died from tuberculosis (TB) — an infectious disease that mainly affects the lungs. A major obstacle in the clinical treatment of TB is the long therapy time required to clear the infection. An infected patient needs to take antibiotics for over 6 to 9 months to prevent a relapse — a duration so long that many discontinue their medications.
Tuberculosis, caused by the bacteria Mycobacterium tuberculosis, is a leading cause of death worldwide. In 2017 alone, 10 million people across the globe were affected by the disease, and about 1.6 million succumbed to it.
The success rate of the ambitious Revised National Tuberculosis Control Programme (RNTCP), driven by the Government of India, is appaling, reports a study.
This study, by researchers from Hungary, India, France and the USA, explored the potential of some new chemical compounds as therapeutic agents against tuberculosis. Such compounds represent new possibilities for further anti-TB drug development.
A collaborative study by researchers from Punjab University, Indian Institute of Technology (IIT) Delhi, Banasthali University, TERI University and the Jawaharlal Nehru University has identified how a particular gene in Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), mutates to avoid the action of antibiotics.
